Clinical Trials Using Cabozantinib S-malate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Cabozantinib S-malate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-36 of 36

  • Cabozantinib and Pembrolizumab for the Treatment of Stage IIIC-IV Melanoma

    This phase I / II trial studies the best dose of cabozantinib when given together with pembrolizumab and to see how well it works in treating patients with stage IIIC-IV melanoma. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and pembrolizumab may work better in treating patients with melanoma compared to pembrolizumab alone.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Cabozantinib and Durvalumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies

    This phase I / II trial studies the side effects and best dose of cabozantinib when given together with durvalumab in treating patients with stage III-IV gastroesophageal cancer and other gastrointestinal malignancies. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and durvalumab may work better in treating patients with gastroesophageal cancer and other gastrointestinal malignancies compared to cabozantinib or durvalumab alone.
    Location: University of Kansas Cancer Center, Kansas City, Kansas

  • Cabozantinib S-malate and Avelumab in Treating Participants with Metastatic Kidney Cancer

    This phase I trial studies the side effects and best dose of cabozantinib s-malate and avelumab in treating participants with kidney cancer that has spread to other places in the body. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib s-malate and avelumab may work better in treating participants with metastatic kidney cancer.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Cabozantinib S-malate in Treating Children with Recurrent or Refractory High Grade Glioma

    This phase II trial studies the side effects and how well cabozantinib S-malate works in treating children with high grade glioma that has come back or does not respond to treatment. Cabozantinib S-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Riley Hospital for Children, Indianapolis, Indiana

  • Cabozantinib S-malate in Treating Patients with Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

    This pilot phase II trial studies how well cabozantinib s-malate works in treating patients with pheochromocytomas or paragangliomas that have spread from the primary site to other places in the body (metastatic) and cannot be removed by surgery (unresectable). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking the growth of new blood vessels necessary for tumor growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Cabozantinib-s-malate in Treating Patients with Previously Treated Non-small Cell Lung Cancer and Brain Metastases

    This phase II trial studies how well cabozantinib-s-malate works in treating patients with previously treated non-small cell lung cancer that has spread to the brain. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Cabozantinib-S-Malate as First-Line Therapy in Treating Patients With Radioiodine-Refractory Thyroid Cancer That is Metastatic or Cannot Be Removed By Surgery

    This phase II clinical trial studies how well cabozantinib-s-malate works as first-line therapy in treating patients with radioiodine-refractory thyroid cancer that has spread to other places in the body or cannot be removed by surgery. Cabozantinib may result in disease response and possibly allow for a prolonged period of response or stabilization of thyroid cancer by blocking some of the enzymes needed for cell growth.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

    This phase II trial studies how well cabozantinib and pembrolizumab work for the first-line treatment of patients with liver cancer who are not eligible for local therapy (i.e. advanced stage). Cabozantinib may stop the growth of tumor cells by blocking some cell surface receptors and signaling pathways inside the tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer. Giving cabozantinib and pembrolizumab together may work better in treating patients with advanced liver cancer compared to cabozantinib or pembrolizumab alone.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Efficacy and Safety Study of AVB-S6-500 in Patients With Clear Cell Renal Cell Carcinoma

    This is a Phase 1b / 2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib in subjects with advanced clear cell renal cell carcinoma (ccRCC) that have received front-line treatment. The phase 1b portion of the study is open label and patients will receive AVB-S6-500+Cabozantinib in 3+3 dose escalation. The Phase 2 portion of the study is randomized, open-label study to compare efficacy and tolerability of AVB-S6-500+cabozantinib versus cabozantinib alone
    Location: 2 locations

  • Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

    This phase II trial studies how well paclitaxel with and without nivolumab works in treating patients with soft tissue sarcoma that have not received taxane drugs, and how well nivolumab and cabozantinib work in treating taxane pretreated patients with soft tissue sarcoma. Nivolumab works through the body’s immune system to help the immune system act against tumor cells. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial is being done to see if the combination of nivolumab and paclitaxel or cabozantinib can shrink soft tissue sarcoma and possibly prevent it from coming back.
    Location: Location information is not yet available.

  • Cabozantinib S-malate and Nivolumab in Treating Patients with Advanced, Recurrent, or Metastatic Endometrial Cancer

    This randomized phase II trial studies how well cabozantinib s-malate and nivolumab work in treating patients with endometrial that has come back (recurrent) or spread to other places in the body (advanced or metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may work better in treating endometrial cancer.
    Location: 32 locations